Aravive — Investor Presentation (March 2020)
30 slides from Aravive's investor presentation, Mar 27, 2020
Slide 1: Aravive Corporate Presentation March 2020
Halting Disease Progression in its Tracks © 2020 Aravive, Inc. Aravive Corporate Presentation March 2020 Exhibit 99.2
Slide 2: Important Information: Forward-Looking Statements
Important Information © 2020 Aravive, Inc. Forward-Looking Statements This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward- looking
Slide 3: Company Overview
Company Overview The Company Lead Clinical Program (AVB-500) Aravive is a clinical stage company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis NASDAQ-listed company (ARAV) Offices in Houston, TX (hdqtrs.) and Palo Alto, CA $20 mill
Slide 4: Pipeline Focused on GAS6/AXL Signaling in Oncology & Fibrosis
Pipeline Focused on GAS6/AXL Signaling in Oncology & Fibrosis Indication Preclinical Phase 1 Phase 1 *Phase 1b Phase 3 AVB-S6-TBD Ovarian Cancer platinum resistant (PAC or PLD combination) Clear Cell Renal Cancer 2L (cabozantanib combination) Advanced Urothelial Cancer (PDLI combination) Kidney Fibr
Slide 5: AXL Tyrosine Kinase Promotes Invasion, Metastasis, and Resistance
AXL Tyrosine Kinase Promotes Invasion, Metastasis, and Resistance AXL is a member of tyrosine kinases that include Tyro3, AXL, and Mer (TAMs) AXL is activated by a single ligand, growth arrest–specific 6 (GAS6); Mer and Tyro3 can be activated by GAS6 and Protein S 1 Upregulated in many cancers 2, AX
Slide 6: GAS6/AXL Signaling: Decoy Receptor is the Best Approach
GAS6/AXL Signaling: Decoy Receptor is the Best Approach for Potent and Selective Inhibition WT AXL has pM Affinity; AVB-500 AXL Decoy has fM Affinity Selectivity limited by RTK homology Off-target toxicity Multiple resistance mechanisms Many potential competitors AXL or GAS6 Antibody Tyrosine Kinase
Slide 7: Other Drugs Targeting AXL Signaling are Not Selective
Other Drugs Targeting AXL Signaling in Clinical Development are Not Selective Drug (Stage) Company Target Selective for AXL AVB-500 (Ph Ib/II) Aravive GAS6 YES Gilterinib (Market) Astellas AXL (Multi-kinase) NO Cabozantinib (Market) Exelixis AXL (Multi-kinase) NO Sitravatinib (Ph III) Mirati (BeiGen
Slide 8: AVB-500: A Novel Approach to Selectively Inhibit AXL Signaling
AVB-500: A Novel Approach to Selectively Inhibit AXL Signaling Decoy receptor engineered for very high affinity for GAS6 – ~200 fold greater than native AXL Favorable safety and PK profile GAS6 not needed by normal tissue GLP preclinical studies demonstrate ≥ 30-fold safety margin (relative to max f
Slide 9: Strong Rationale for Inhibiting GAS6/AXL in Platinum Resistant Ovarian Cancer
Strong Rationale for Inhibiting GAS6/AXL Signaling with AVB-500 in Platinum Resistant Metastatic Ovarian Cancer Expression in 0% (0/10) of normal ovarian tissue Expression in 73% (219/297) ovarian tumor samples including low grade serous, endometroid and advanced stage tumors1 Preclinical in vitro 1
Slide 10: AVB-500: Clinical Program in Expanded Phase 1b/2 Trial
AVB-500: Clinical Program Currently in Expanded Phase 1b/2 Trial With Early Proof-of-Concept Data Fast-track designation granted by the FDA for platinum-resistant ovarian cancer; 10 and 15 mg/kg dose enrollment completed & now enrolling 20 mg/kg dose Well-tolerated to date and no anticipated drug-dr
Slide 11: Key Eligibility Criteria for P1b Study in Platinum-Resistant Ovarian Cancer
Key Eligibility Criteria for P1b Study in Platinum-Resistant Ovarian Cancer NOS= Not Otherwise Specified | ECOG= Eastem Cooperative Oncology Group © 2020 Aravive, Inc. 1-3 prior lines Measurable disease Platinum free interval ≤ 6mo after most recent platinum-containing regimen Adenocarcinoma NOS, hi
Slide 12: Currently in mg/kg Cohort of P1b Study of AVB-500
Currently in 20 mg/kg cohort of P1b Study of AVB-500 in Platinum-Resistant Ovarian Cancer AVB-500 (AVB): Initial dose 10 mg/kg q14 days Pegylated liposomal doxorubicin (PLD): 40 mg/m2 d1; 28 day cycle Paclitaxel (PAC): 80 mg/m2 day 1, day 8, day 15; 28-day cycle Maintenance dosing on AVB-500 monothe
Slide 13: Safety Summary from Phase 1B PROC Study to Date
40 patients total have been dosed at 10mg/kg 6 patients have been dosed at 15mg/kg Enrolling 12 patients into 20mg/kg cohort; 4 patients dosed AVB-500 well-tolerated No serious and unexpected adverse reactions No dose limiting toxicities Infusion reactions managed by premedication regimen © 2020 Ara
Slide 14: Exposure-Response Analysis Demonstrated AVB-500 Levels Predict Clinical Benefit
Exposure-Response Analysis Demonstrated AVB-500 Levels at 10mg/kg Dose Predict Clinical Benefit © 2020 Aravive, Inc. Above Minimal Efficacious Exposure Below Minimal Efficacious Exposure Number of Patients (n) 17 14 Complete Response (CR) 1 (6%) 0 Partial Response (PR) 4 (24%) 2 (14%) Overall Respon
Slide 15: AVB-500 + Chemo Shows Improved Clinical Benefit in Patient Subsets
AVB-500 (10mg/kg) + Chemo Shows Improved Clinical Benefit in Patient Subsets That Generally Respond Poorly to Chemo ORR= objective response rate; CR=complete response; PR=partial response; SD=stable disease; CBR=clinical benefit rate; PD=progressive disease Historical control data from European Jour
Slide 16: AVB-500 + Chemo Shows Improved Clinical Benefit in Patient Subsets
AVB-500 (10mg/kg) + Chemo Shows Improved Clinical Benefit in Patient Subsets That Generally Respond Poorly to Chemo Historical control data from Cancer Chemotherapy and Pharmacology (2019) 84:33-39 37 12 patients in AVB-500 +chemo group overall, 6 patients in the high exposure AVB-500 +chemo group a
Slide 17: Best Response by RECISTv1.1 for First 31 Patients
Best Response Determined by Investigator-Assessed RECISTv1.1 for First 31 Patients (10mg/kg): One CR © 2020 Aravive, Inc. Note: 2 pts who were PD at best response (Pac arm) are excluded from the waterfall PLD Pac High exposure patients
Slide 18: Summary of First Patients' Response as of October 2019 CT Scans
Summary of First 31 Patients’ Response as of October 31 2019 CT Scans PAC PLD Partial response Progressed Complete response Stable disease represented by continuous bar * * * * * * * * * * * * * * * * * * High exposure patients Withdrew consent and off study © 2020 Aravive, Inc. As of Oct 31, 2019 p
Slide 19: Comparable Demographics and Baseline Characteristics
Comparable Demographics and Baseline Characteristics Confirming AVB-500 Exposure Drives Anti-Tumor Activity Above Minimal Efficacious Concentration Below Minimal Efficacious Concentration Age, years median (min, max) 71 (52-82) 63.0 (53-80) Prior lines* 1 (%) 6 (35.3%) 2 (14.3%) 2 (%) 8 (47.1%) 6 (4
Slide 20: Next Steps
Next Steps Data confirm strategy to investigate higher doses in the current Phase 1b study to determine if a greater proportion of patients achieve high drug exposure levels PK modeling predict a dose of 20 mg/kg should allow >90% of patients to achieve desired high exposure levels Anticipate PK and
Slide 21: Randomized Ph 2/3 Study Following Completion of Ph 1b Dose Escalation
Randomized Ph 2/3 Study Following Completion of Ph 1 Dose Escalation in PROC Patients: P1b Will Determine RP2D Anticipate initiating 2H20, subject to the impact of COVID-19 Same population as P1b portion Effect size from P1b will drive regulatory strategy, statistical plan, Ns Gain agreement from FD
Slide 22: Rationale for AVB-500 in Kidney Cancer
Rationale for AVB-500 in Kidney Cancer Strong biological rationale for clear cell Renal Cell Cancer1 VHL tumor suppressor gene mutated, causes increase in AXL AXL/GAS6 levels predict prognosis & survival in human1 Strong in vivo activity in preclinical models1,2 Single agent Combo with TKI 2 Xiao et
Slide 23: Overview of P1b/P2 Clear Cell Renal Cell Carcinoma
Overview of P1b/P2 Clear Cell Renal Cell Carcinoma Positioning AVB-500 in the Evolving Treatment Landscape Histologically confirmed stage IV ccRCC (according to the American Joint Commission on Cancer, seventh edition, classification) progressed on/after or intolerant to 1L Cabozantinib is used most
Slide 24: AXL Promotes a Suppressive Myeloid Micro-environment
AXL Promotes a Suppressive Myeloid Micro-environment ISTs Investigating Combinations of AVB-500 + PDL1 inhibitor AXL presence Decreases tumor T cells (killer) infiltration Decreases Tumor antigen presentation Increases suppressive myeloid cells and macrophages AXL loss Increases Tumor antigen expres
Slide 25: Strong Biological Rationale for IgA Nephropathy
Strong biological rationale for IgA nephropathy (IgAN)1 GAS6 is more highly expressed in IgAN tissue relative to normal tissue GAS6 stimulates mesangial cell proliferation GAS6 expression correlates with severity of IgA Nephropathy and predict prognosis in humans Strong in vivo activity in preclinic
Slide 26: Overview of Phase 2A IgAN Study
Overview of Phase 2A IgAN Study Small (N of 12-24) Proof of Concept Study in IgA patients Sites in USA and Ukraine Diagnosis of biopsy-proven IgAN Proteinuria ≥ 1g to 3g/24hr Monitor safety, PK/PD Ensure sGAS6 levels suppressed throughout dosing interval Open-label Monitor proteinuria and other rena
Slide 27: Experienced, Methodical, Efficient Development Execution
Experienced, Methodical, Efficient Development Execution Strong Clinical Development Team © 2020 Aravive, Inc. 2Q 2019- POM in Ovarian Cancer 2Q 2019- Tolerability in Ovarian Cancer 3Q 2019- Early POC in Ovarian Cancer 3Q 2019- Expanded P1b Ovarian Cancer 4Q2019- Kidney fibrosis trial initiation 1Q
Slide 28: Financials and Capitalization
Financials and Capitalization NASDAQ: ARAV; Shares Outstanding*: 15.0M basic Cash and cash equivalents*: $65M Cash and cash equivalents expected to enable the company to fund its operating plans into 2022 © 2020 Aravive, Inc. * As of December 31, 2019
Slide 29: AVB-500 Offers First- and Best-In-Class Opportunity in Oncology
AVB-500 Offers First- and Best-In-Class Opportunity in Oncology Uniquely positioned in competitive landscape Robust pipeline addressing significant drivers of mortality in oncology and fibrosis: metastasis and drug resistance © 2020 Aravive, Inc. AVB-500: high affinity decoy protein, a potent and se
Slide 30: Thank You
Halting Disease Progression in its Tracks © 2020 Aravive, Inc. Thank You